| Adipocytokines: mediators linking adipose tissue, inflammation and immunity H Tilg, AR Moschen Nature reviews immunology 6 (10), 772-783, 2006 | 4142 | 2006 |
| Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis H Tilg, AR Moschen Hepatology 52 (5), 1836-1846, 2010 | 2872 | 2010 |
| EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease European Association for the Study of the Liver (EASL), European Association ... Obesity facts 9 (2), 65-90, 2016 | 2771 | 2016 |
| 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: part 1: diagnosis and medical management F Gomollón, A Dignass, V Annese, H Tilg, G Van Assche, JO Lindsay, ... Journal of Crohn's and Colitis 11 (1), 3-25, 2017 | 2388 | 2017 |
| Intestinal permeability–a new target for disease prevention and therapy SC Bischoff, G Barbara, W Buurman, T Ockhuizen, JD Schulzke, M Serino, ... BMC gastroenterology 14, 1-25, 2014 | 2051 | 2014 |
| XBP1 links ER stress to intestinal inflammation and confers genetic risk for human inflammatory bowel disease A Kaser, AH Lee, A Franke, JN Glickman, S Zeissig, H Tilg, ... Cell 134 (5), 743-756, 2008 | 1649 | 2008 |
| Gut microbiome and health: mechanistic insights WM De Vos, H Tilg, M Van Hul, PD Cani Gut 71 (5), 1020-1032, 2022 | 1425 | 2022 |
| Visfatin, an adipocytokine with proinflammatory and immunomodulating properties AR Moschen, A Kaser, B Enrich, B Mosheimer, M Theurl, H Niederegger, ... The Journal of Immunology 178 (3), 1748-1758, 2007 | 1400 | 2007 |
| Cytokines in alcoholic and nonalcoholic steatohepatitis H Tilg, AM Diehl New England Journal of Medicine 343 (20), 1467-1476, 2000 | 1390 | 2000 |
| Gut microbiome development along the colorectal adenoma–carcinoma sequence Q Feng, S Liang, H Jia, A Stadlmayr, L Tang, Z Lan, D Zhang, H Xia, X Xu, ... Nature communications 6 (1), 6528, 2015 | 1315 | 2015 |
| European consensus conference on faecal microbiota transplantation in clinical practice G Cammarota, G Ianiro, H Tilg, M Rajilić-Stojanović, P Kump, R Satokari, ... Gut 66 (4), 569-580, 2017 | 1241 | 2017 |
| Inflammatory mechanisms in the regulation of insulin resistance H Tilg, AR Moschen Molecular medicine 14, 222-231, 2008 | 1206 | 2008 |
| Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55 H Tilg, E Trehu, MB Atkins, CA Dinarello, JW Mier | 1193 | 1994 |
| Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases LA Adams, QM Anstee, H Tilg, G Targher Gut 66 (6), 1138-1153, 2017 | 1154 | 2017 |
| Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes AM Wolf, D Wolf, H Rumpold, B Enrich, H Tilg Biochemical and biophysical research communications 323 (2), 630-635, 2004 | 1108 | 2004 |
| Gut microbiome, obesity, and metabolic dysfunction H Tilg, A Kaser The Journal of clinical investigation 121 (6), 2126-2132, 2011 | 1107 | 2011 |
| Metagenomic analysis of faecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer J Yu, Q Feng, SH Wong, D Zhang, Q yi Liang, Y Qin, L Tang, H Zhao, ... Gut 66 (1), 70-78, 2017 | 1092 | 2017 |
| Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease JF Rahier, F Magro, C Abreu, A Armuzzi, S Ben-Horin, Y Chowers, ... Journal of Crohn's and Colitis 8 (6), 443-468, 2014 | 1056 | 2014 |
| NAFLD and diabetes mellitus H Tilg, AR Moschen, M Roden Nature reviews Gastroenterology & hepatology 14 (1), 32-42, 2017 | 1017 | 2017 |
| The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations G Van Assche, A Dignass, W Reinisch, CJ van der Woude, A Sturm, ... Journal of Crohn's and Colitis 4 (1), 63-101, 2010 | 973 | 2010 |
